Meeting NewsVideo

VIDEO: Dark adaptation a biomarker for AMD

NEW ORLEANS – Practitioners can use the AdaptDx by Maculogix to test a patient’s dark adaptation, which can be a biomarker for AMD, according to Bill McPhee, CEO of Maculogix.

“We wanted to launch a technology that will allow us to find the disease earlier, faster, smarter and easier, and it’s now available for all eye care practitioners,” he said here at the OIS meeting during SECO.

NEW ORLEANS – Practitioners can use the AdaptDx by Maculogix to test a patient’s dark adaptation, which can be a biomarker for AMD, according to Bill McPhee, CEO of Maculogix.

“We wanted to launch a technology that will allow us to find the disease earlier, faster, smarter and easier, and it’s now available for all eye care practitioners,” he said here at the OIS meeting during SECO.

    See more from SECO